With each day seemingly bringing a new case of anthrax infection, interest in developing treatments for the potentially fatal disease has reached an all-time high. To that end, two reports released yesterday by the journal Nature should help, providing greater understanding of the mechanism by which the anthrax toxin kills host cells.
Previous work had shown that after entering a host, the anthrax bacterium, Bacillus anthracis (see image), secretes a toxin comprised of three parts. One of these, protective antigen (PA), binds to the outside of the cell and mediates entry of the other two¿edema factor (EF) and lethal factor (LF). Once inside, EF and LF use enzymes to destroy the cell.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
In one of the new studies, John A. T. Young of the University of Wisconsin-Madison and colleagues identified the receptor that PA binds to in humans. Starting with cells resistant to the anthrax toxin, the scientists first determined that resistance stems from the absence of a receptor for the anthrax toxin. They then introduced genes into the cells until they found one that restored receptor production. It turns out the protein produced by that gene, dubbed anthrax toxin receptor (ATR), features a region that protrudes from the cell membrane, providing a docking site for PA. In subsequent in vitro experiments, adding synthesized copies of the receptor to the extracellular environment protected cells from anthrax by providing alternative binding sites for the toxin. "The identification of ATR," the team writes, "now allows for a more detailed investigation of the mechanism of uptake by cells of anthrax toxin."
The second report, by Robert Liddington of the Burnham Institute in La Jolla, Calif., and colleagues, describes in detail the structure of LF. This protein "has evolved through a process of gene duplication, mutation and fusion, into an enzyme with high and unusual specificity," the authors note. They conclude that the new structural information "can be used in the design of therapeutic agents that would block the activity of LF." Of course, such therapies are still years away from practical use, so for now treatment will continue to rely on the use of antibiotics to kill the anthrax bacterium.